Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: A prospective study

被引:58
作者
Tiller, K
Meiser, B
Butow, P
Clifton, M
Thewes, B
Friedlander, M
Tucker, K
机构
[1] Prince Wales Hosp, Dept Med Oncol, Sydney, NSW, Australia
[2] Royal N Shore Hosp, Dept Psychol Med, Sydney, NSW, Australia
[3] Univ Sydney, Med Psychol Unit, Sydney, NSW 2006, Australia
基金
英国医学研究理事会;
关键词
prophylactic oophorectomy; prospective study;
D O I
10.1006/gyno.2002.6737
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. The objectives of this study were twofold: to prospectively assess whether expressed intention to undergo prophylactic oophorectomy translated into uptake and to evaluate the psychological impact of the procedure in a sample of unaffected women with a strong family history of breast/ovarian cancer. Methods. Ninety-five women, initially assessed at the time of their first attendance at a familial cancer clinic, were followed-up 3 years later. A total of 22 women (23.2%) in this study had undergone a prophylactic oophorectomy. Ten women (10.5%) who had undergone a prophylactic oophorectomy during the 3-year follow-up period were compared to 73 women (76.9%) who did not have a prophylactic oophorectomy. Twelve women (12.6%) who had the procedure prior to study entry were also assessed for psychological adjustment and associated information needs. Results. Age emerged as a significant predictor of uptake of prophylactic oophorectomy (chi(2)=7.13, P=0.009). Among those who had the procedure after study entry, a significant reduction in ovarian cancer anxiety was observed (Z=-2.19, P=0.029). Of the 22 women who had undergone a prophylactic oophorectomy in total (both before and after study entry), 86.4% reported a high degree of satisfaction with their decision to have the procedure. A low level of screening uptake was also reported by women who did not have a prophylactic oophorectomy but for whom screening was recommended. Conclusion. Findings demonstrate that prophylactic oophorectomy is successful in reducing anxiety about ovarian cancer. The results also suggest that women perceive that the benefit of anxiety reduction may outweigh the potentially adverse effects of the procedure, given that women expressed a high level of satisfaction with their decision. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:212 / 219
页数:8
相关论文
共 37 条
  • [1] [Anonymous], 1995, JAMA, V273, P491
  • [2] The performance of screening tests for ovarian cancer: results of a systematic review
    Bell, R
    Petticrew, M
    Sheldon, T
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (11): : 1136 - 1147
  • [3] Berchuck A, 1999, CANCER, V86, P2517, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2517::AID-CNCR8>3.0.CO
  • [4] 2-B
  • [5] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .2. BRCA1 and BRCA2
    Burke, W
    Daly, M
    Garber, J
    Botkin, J
    Kahn, MJE
    Lynch, P
    McTierman, A
    Offit, K
    Perlman, J
    Petersen, G
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (12): : 997 - 1003
  • [6] Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer
    Burke, W
    Petersen, G
    Lynch, P
    Botkin, J
    Daly, M
    Garber, J
    Kahn, MJE
    McTiernan, A
    Offit, K
    Thomson, E
    Varricchio, C
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11): : 915 - 919
  • [7] EASTON DF, 1995, AM J HUM GENET, V56, P265
  • [8] EASTON DF, 1993, AM J HUM GENET, V52, P678
  • [9] Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee
    Eisinger, F
    Alby, N
    Bremond, A
    Dauplat, J
    Espie, M
    Janiaud, P
    Kuttenn, F
    Lebrun, JP
    Lefranc, JP
    Pierret, J
    Sobol, H
    Stoppa-Lyonnet, D
    Thouvenin, D
    Tristant, H
    Feingold, J
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (09) : 939 - 950
  • [10] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695